Key takeaways
Omvoh (mirikizumab) and Skyrizi (risankizumab) are both medications used to treat inflammatory conditions, and they work by blocking interleukin-23 (IL-23) to reduce inflammation. Omvoh is specifically FDA-approved for moderate-to-severe ulcerative colitis in adults, while Skyrizi is approved for that condition as well as moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. Omvoh is administered initially as intravenous infusions for the first three doses, followed by monthly subcutaneous (under the skin) injections. In contrast, Skyrizi starts with intravenous infusions for ulcerative colitis and then switches to subcutaneous injections every 2 or 3 months. For subcutaneous injection forms, Omvoh is available as prefilled pens, while Skyrizi offers prefilled syringes, pens, and an On-Body Injector. Both medications can cause side effects like injection site reactions, joint pain, and increased risk of infections. Additionally, both medications require caution with live vaccines due to their immunosuppressive effects.
